MRKR logo

MRKRMarker Therapeutics Inc

$1.40
$0.05
(3.40%)
Today
Closed $1.42
$0.0184
(1.30%)
After Hours
Updated: 04:50 PM EDT
Mkt Cap$24.51M
Vol52,900.00
News
all
press releases
MARKER THERAPEUTICS (MRKR) Upgraded to Buy: What Does It Mean for the Stock?
MARKER THERAPEUTICS (MRKR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
News Placeholder
More News
News Placeholder
ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates
PROKIDNEY CP (PROK) delivered earnings and revenue surprises of -7.69% and +222.86%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
BioStem Technologies, Inc. (BSEM) Reports Q1 Loss, Tops Revenue Estimates
BioStem Technologies, Inc. (BSEM) delivered earnings and revenue surprises of -85.71% and +7.64%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
MARKER THERAPEUTICS, INC. (MRKR) Reports Q4 Loss, Tops Revenue Estimates
MARKER THERAPEUTICS (MRKR) delivered earnings and revenue surprises of +80.49% and +83.83%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Profound Medical (PROF) Reports Q4 Loss, Misses Revenue Estimates
Profound Medical (PROF) delivered earnings and revenue surprises of 0.00% and -21.87%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know
Marker Therapeutics' shares jump 114% in three months as early MT-601 data showed strong responses, advanced into dose expansion, and lifted investor confidence.
Zacks
News Placeholder
Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics
Soleno Therapeutics leads a rebound in small drug stocks as innovation, pipeline progress and M&A activity fuel optimism for 2026.
Zacks
News Placeholder
MARKER THERAPEUTICS, INC. (MRKR) Now Trades Above Golden Cross: Time to Buy?
Is it a good or bad thing when a stock experiences a golden cross technical event?
Zacks
News Placeholder
5 Small Drug Stocks to Buy as Industry Recovery Picks Up
Innovation is at its peak in the Zacks Medical-Drugs industry. SLNO, NKTR, RIGL, IRWD and MRKR may prove to be good additions to one's portfolio.
Zacks
<
...
1
>

Advertisement|Remove ads.